Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Adagio Medical Holdings (ADGM) Shares Outstanding (Weighted Average) (2023 - 2026)

Adagio Medical Holdings has reported Shares Outstanding (Weighted Average) over the past 4 years, most recently at $22.2 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 44.45% to $22.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $22.2 million through Mar 2026, up 44.45% year-over-year, with the annual reading at $7.5 million for FY2025, 49.04% down from the prior year.
  • Shares Outstanding (Weighted Average) was $22.2 million for Q1 2026 at Adagio Medical Holdings, up from $7.5 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $22.2 million in Q1 2026 and troughed at $1.0 in Q2 2024.
  • The 4-year median for Shares Outstanding (Weighted Average) is $14.1 million (2024), against an average of $9.7 million.
  • The largest YoY upside for Shares Outstanding (Weighted Average) was 1537854200.0% in 2025 against a maximum downside of 49.04% in 2025.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $759814.0 in 2023, then skyrocketed by 1844.25% to $14.8 million in 2024, then crashed by 49.04% to $7.5 million in 2025, then surged by 195.01% to $22.2 million in 2026.
  • Per Business Quant, the three most recent readings for ADGM's Shares Outstanding (Weighted Average) are $22.2 million (Q1 2026), $7.5 million (Q4 2025), and $15.4 million (Q3 2025).